主页 文献库文献详情
PMID: 42188988 已发表 · ppublish 英语

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

NEJM evidence ·第 5 卷 ·第 6 期 ·2026-06-00

Civettini I, Malighetti F, Villa M, Crippa V, Aroldi A, Cavalca F, Graudenzi A, Lanino L, Maggioni G, Haferlach T, Fenaux P, Platzbecker U, Díez-Campelo M, Borin LM, Fumagalli M, Zappaterra A, Manghisi B, Al Ali NH, Sallman DA, Padron E, Xie Z, Chan O, Zeidan AM, Mologni L, Piazza R, Komrokji RS, Della Porta MG, Gambacorti-Passerini C, Ramazzotti D

摘要

Myelodysplastic syndromes are clonal hematopoietic stem cell disorders characterized by multistep molecular evolution and a variable risk of leukemic transformation. Given this prognostic heterogeneity, accurate risk stratification is essential for clinical decision-making. We developed ProgEvo, a proprietary framework that infers molecular evolutionary trajectories and integrates them with clinical data to improve prognostic accuracy. ProgEvo was trained on 2519 patients in cBioPortal (https://www.cbioportal.org) and validated using two external cohorts: Genomed4All (2043 patients) and a Moffitt Cancer Center (MCC) cohort (2157 patients). Directional evolutionary routes were inferred and selected for prognostic modeling if they were consistently associated with leukemia-free survival. A multivariable feature selection strategy was applied to integrate evolution-consistent variables into the existing IPSS-M model. ProgEvo identified 1765 gene co-occurrences aggregated into 45 directional evolutionary routes. Of these, 18 were validated in the Genomed4All cohort. Five evolution-informed variables, two directional routes (Additional Sex Combs-Like 1 [ASXL1]→KRAS Proto-Oncogene [KRAS] and Serine and Arginine-Rich Splicing Factor 2 [SRSF2]→NRAS Proto-Oncogene [NRAS]), one co-occurrence (NRAS/RUNX Family Transcription Factor 1 [RUNX1]), and two early mutations (ATRX [ATRX Chromatin Remodeler] and Janus Kinase 2 [JAK2]) were integrated into IPSS-M to generate IPSS-M-Evo. The model with "-Evo" improved discrimination for both leukemia-free survival and overall survival, with over 40% of patients restratified in the Genomed4All data. The performance of the model was further confirmed in the MCC cohort. ProgEvo enabled inference of a molecular evolution model and integration of evolution-informed covariates into clinical prognostic frameworks, supporting the development of the IPSS-M-Evo model. A free web-based tool allows clinicians to calculate the IPSS-M-Evo score and match individual mutational profiles to cohort-derived evolutionary trajectories (https://evoclin.unimib.it/tools/evolution-graphs.html and https://evoclin.unimib.it/tools/ipssmevo.html). (Funded by the European Union and others.).

文献信息
期刊
NEJM evidence
期刊简称
NEJM Evid
ISSN
2766-5526
发表日期
2026-06-00
语言
英语
国家/地区
United States
NLM ID
9918317485806676
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]